ADA Technologies, Inc. (ADA)
received a $149,121 grant from the National Cancer Institute* for research and
development of nanotechnology imaging and sensing platforms for improved detection
and diagnosis of cancer.
ADA’s research focuses on developing a nano-enabled sensing platform
for analysis of biomolecules, such as cancer biomarkers, that is more sensitive
than existing technologies. Analysis platforms that provide high sensitivity
and high throughput are critical to cancer biomarker detection.
“Our research will provide the scientific and medical communities with
a reliable, ready-to-use platform that is capable of detecting multiple biomolecules
to facilitate cancer biomarker screening and improve cancer diagnosis,”
said Xichun Zhou, ADA principal investigator.
ADA’s R&D efforts related to nanotechnology imaging and sensing platforms
began in 2007.
*This project is wholly funded with Federal funds from the National Cancer
Institute, National Institutes of Health, Department of Health and Human Services,
under Contract No. HHSN261200800061C.